Critically, it does not bind to the growth hormone receptor and does not raise IGF-1 levels.[1] This means its effects stay localized to fat metabolism, making it a much more targeted option than full hGH therapy
A phase 2 trial published in the New England Journal of Medicine showed average weight loss of over 24% at 48 weeks, and the first phase 3 results in December 2025 suggested that average weight loss could be around 28 to 29%
Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on [PMID: 27627764] Laboratory literature summary: Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed
Saline works perfectly for same-day administration protocols
(1) ber die DOCTOLIB App (2) ber unseren Telefonassistenten (3) per Email